Optimized wavelength gap for improved StO2 measurement

• US 20050277818A1
• Filed: 05/18/2005
• Published: 12/15/2005
• Est. Priority Date: 05/18/2004
• Status: Active Grant

• Current Assignee: Hutchinson Technology Incorporated (TDK Corporation)
• Original Assignee: Hutchinson Technology Incorporated (TDK Corporation)
• Inventors: Myers, Dean E.
• Granted Patent: US 7,613,489 B2
• Time in Patent Office: Days
• US Class Current: 600/323
• CPC Class Codes: A61B 2560/0233 Optical standards
• CPC Class Codes: A61B 5/14551 for measuring blood gases
• CPC Class Codes: A61B 5/7239 using differentiation including higher order derivatives

Abstract

A method and system for producing improved more accurate measurements of oxyhemoglobin levels in tissue when measured using near infrared spectroscopy (NIRS). Light sources and processing methods are selected to such that the effects of a confounding chromophore in the tissue under study are minimized.

Claims

1. A method for determining the level of hemoglobin oxygenation in tissue, comprising the steps of:

illuminating the tissue under study using light having at least the wavelengths of substantially 692 nm, 720 nm, 732 nm, 748 nm, 760 nm and 788 nm;

sensing light that has passed through a portion of the tissue at a predetermined distance from the source of the illumination, determining a value of attenuation of light at each of wavelengths of illumination of the tissue;

determining a second derivative value of the light attenuation at 720 nm through the equation (Second Derivative Attenuation)₇₂₀=Attenuation₇₄₈−

2(Attenuation₇₂₀)+Attenuation₆₉₂;

determining a second derivative value of the light attenuation at 760 nm through the equation (Second Derivative Attenuation)₇₆₀=Attenuation₇₈₈−

2(Attenuation₇₆₀)+Attenuation₇₃₂;

determining a scaled (Second Derivative Attenuation)₇₂₀ as a function of the (Second Derivative Attenuation)₇₂₀ divided by the (Second Derivative Attenuation)₇₆₀;

and comparing the scaled (Second Derivative Attenuation)₇₂₀ to stored data relating hemoglobin oxygenation to the scaled (Second Derivative Attenuation)₇₂₀.

2. A method for determining the level of hemoglobin oxygenation in tissue, comprising the steps of:

illuminating the tissue under study using light having at least the wavelengths of substantially 680 nm, 720 nm, 732 nm, 760 nm and 788 nm;

sensing light that has passed through a portion of the tissue at a predetermined distance from the source of the illumination;

determining a value of attenuation of light at each of wavelengths of illumination of the tissue;

determining a second derivative value of the light attenuation at 720 nm through the equation (Second Derivative Attenuation)₇₂₀=Attenuation₇₆₀−

2(Attenuation₇₂₀)+Attenuation₆₈₀;

determining a second derivative value of the light attenuation at 760 nm through the equation (Second Derivative Attenuation)₇₆₀=Attenuation₇₈₈−

2(Attenuation₇₆₀)+Attenuation₇₃₂;

determining a scaled (Second Derivative Attenuation)₇₂₀ as a function of the (Second Derivative Attenuation)₇₂₀ divided by the (Second Derivative Attenuation)₇₆₀; and

comparing the scaled (Second Derivative Attenuation)₇₂₀ to stored data relating hemoglobin oxygenation to the scaled (Second Derivative Attenuation)₇₂₀.

3. A method for determining the level of hemoglobin oxygenation in tissue, comprising the steps of:

illuminating the tissue under study using light having at least the wavelengths of substantially 680 nm, 720 nm, 760 nm and 890 nm;

sensing light that has passed through a portion of the tissue at a predetermined distance from the source of the illumination;

determining a value of attenuation of light at each of wavelengths of illumination of the tissue;

determining a second derivative value of the light attenuation at 720 nm through the equation (Second Derivative Attenuation)₇₂₀=Attenuation₇₆₀−

2(Attenuation₇₂₀)+Attenuation₆₈₀;

determining a second derivative value of the light attenuation at 760 nm through the equation (Second Derivative Attenuation)₇₆₀=Attenuation₈₉₀−

2(Attenuation₇₆₀)+Attenuation₇₂₀;

determining a scaled (Second Derivative Attenuation)₇₂₀ as a function of the (Second Derivative Attenuation)₇₂₀ divided by the (Second Derivative Attenuation)₇₆₀;

and comparing the scaled (Second Derivative Attenuation)₇₂₀ to stored data relating hemoglobin oxygenation to the scaled (Second Derivative Attenuation)₇₂₀.

4. A method for determining the level of hemoglobin oxygenation in tissue with at least one confounding chromophore present in the tissue under study, comprising the steps of:

illuminating the tissue under study using light at wavelengths such that scaled 2nd derivative attenuation measurement for the confounding chromophore is substantially similar to the scaled 2nd derivative attenuation measurement for the hemoglobin;

sensing light that has passed through a portion of the tissue at a predetermined distance from the source of the illumination;

determining a value of attenuation of light at each of wavelengths of illumination of the tissue;

determining a second derivative value of the light attenuation at 720 nm, determining a second derivative value of the light attenuation at 760 nm through the equation;

determining a scaled (Second Derivative Attenuation)₇₂₀ as a function of the (Second Derivative Attenuation)₇₂₀ divided by the (Second Derivative Attenuation)₇₆₀; and

comparing the scaled (Second Derivative Attenuation)₇₂₀ to stored data relating hemoglobin oxygenation to the scaled (Second Derivative Attenuation)₇₂₀.

5. The method of claim 4, wherein a wavelength gap between wavelengths used in the illuminating step is dependent upon a hemoglobin oxygenation level.

6. The method of claim 4, wherein a first wavelength gap between wavelengths is used in the illuminating step to determine an initial hemoglobin oxygenation level and a second wavelength gap, dependent upon the initial hemoglobin oxygenation level, is used thereafter.

7. A method for determining the level of a selected chromophore in tissue with at least one confounding chromophore present in the tissue under study, comprising the steps of:

illuminating the tissue under study using light at wavelengths such that scaled 2nd derivative attenuation measurement for the confounding chromophore is substantially similar to the scaled 2nd derivative attenuation measurement for the selected chromophore wherein there is light at at least first and second wavelengths;

sensing light that has passed through a portion of the tissue at a predetermined distance from the source of the illumination, determining a value of attenuation of light at each of wavelengths of illumination of the tissue;

determining a second derivative value of the light attenuation at the first wavelength, determining a second derivative value of the light attenuation at the second wavelength;

determining a scaled Second Derivative Attenuation at the first wavelength as a function of the Second Derivative Attenuation at the first wavelength and the Second Derivative Attenuation at the second wavelength; and

comparing the scaled Second Derivative Attenuation to stored data relating hemoglobin oxygenation to the scaled Second Derivative Attenuation at the first wavelength.

8. The method of claim 7, wherein the first wavelength of light is selected so that the second derivative attenuation of the selected chromophore at the first wavelength is near either a local minimum or maximum and the second wavelength of light is selected so that the second derivative attenuation of the selected chromophore is the other of the local minimum or maximum.

9. The method of claim 7, wherein a wavelength gap between wavelengths used in the illuminating step is dependent upon a hemoglobin oxygenation level.

10. The method of claim 9, wherein a first wavelength gap between wavelengths is used in the illuminating step to determine an initial hemoglobin oxygenation level and a second wavelength gap, dependent upon the initial hemoglobin oxygenation level, is used thereafter.

11. A measurement system for determining a relative concentration of a first form of a chromophore in a tissue sample also having a confounding chromophore, said chromophore comprising at least a first form and a second form, comprising:

(a) means for irradiating said tissue sample with at least first and second wavelengths of light such that scaled 2nd derivative attenuation measurement for the confounding chromophore is substantially similar to the scaled 2nd derivative attenuation measurement for the selected chromophore;

(b) means for detecting the spectral data emitted from said tissue;

(c) means for determining a first 2d derivative spectrum value of the spectral data at a first wavelength within said wavelength range at which the first 2d derivative spectrum value varies with the concentration of the first form of the chromophore;

(d) means for determining a second 2d derivative spectrum value of the spectral data at a second wavelength within said wavelength range at which the second 2d derivative spectrum value varies with a concentration of at least a second form of the chromophore;

(e) means for deriving a scaled, 2d derivative spectrum value from information comprising the first and second 2d derivative spectrum values; and

(f) means for storing a correlation which provides the relative chromophore concentration as a function of the scaled, 2d derivative spectrum value; and

(g) means for determining the relative concentration of the first form of the chromophore in the tissue sample from information comprising the scaled, 2d derivative spectrum value and the correlation.

12. The system of claim 11, wherein the first wavelength of light is selected so that the second derivative attenuation of the selected chromophore at the first wavelength is near either a local minimum or maximum and the second wavelength of light is selected so that the second derivative attenuation of the selected chromophore is the other of the local minimum or maximum.

13. The measurement system of claim 11 wherein said means for storing said correlation is a computer memory.

14. The measurement system of claim 11 wherein said means for determining said relative concentration is a computer.

15. The method of claim 11, wherein a wavelength gap between wavelengths used in the illuminating step is dependent upon a hemoglobin oxygenation level.

16. The method of claim 11, wherein a first wavelength gap between wavelengths is used in the illuminating step to determine an initial hemoglobin oxygenation level and a second wavelength gap, dependent upon the initial hemoglobin oxygenation level, is used thereafter.

17. A system for measuring a relative concentration of a chromophore in a tissue sample which also contains a confounding chromophore, said chromophore comprising at least a first form and a second form, comprising:

(a) a memory comprising data representative of a correlation which provides the relative concentration of the first chromophore as a function of a scaled, 2d derivative spectrum value input, wherein the scaled second derivative spectrum value input is derived from a spectral response obtained from the tissue sample using light at first and second wavelengths such that scaled 2nd derivative attenuation measurement for the confounding chromophore is substantially similar to the scaled 2nd derivative attenuation measurement for the first chromophore;

(b) a light source assembly for generating spectroscopic radiation for irradiating the tissue sample;

(c) a spectroscopic detector for detecting the spectral response emitted by the tissue sample responsive to irradiation with the spectroscopic radiation; and

(d) a control system interfaced with the memory and the spectroscopic detector such that;

(i) the control system generates the scaled, second derivative spectrum value of the tissue sample from information comprising the spectral response of the tissue sample; and

(ii) the control system generates information representative of the relative concentration of the first form of the chromophore in the tissue sample from information comprising the scaled, second derivative spectrum value and the correlation provided in the memory.

18. The system of claim 17, wherein the first wavelength of light is selected so that the second derivative attenuation of the selected chromophore at the first wavelength is near either a local minimum or maximum and the second wavelength of light is selected so that the second derivative attenuation of the selected chromophore is the other of the local minimum or maximum.

19. The system of claim 17, wherein the scaled, 2d derivative spectrum value is obtained from the tissue sample in vivo.

20. The system of claim 17, wherein the spectroscopic radiation is near infrared radiation.

21. The system of claim 17, wherein the light source comprises individual light sources at 680, 720, 760 and 890 nm.

22. The system of claim 17, wherein the light source comprises individual light sources at 692, 720, 732, 748, 760 and 788 nm.

23. The system of claim 17, wherein the light source comprises individual light sources at 680, 720, 732, 760 and 788 nm.

24. The method of claim 17, wherein a wavelength gap between wavelengths used in the illuminating step is dependent upon a hemoglobin oxygenation level.

25. The method of claim 17, wherein a first wavelength gap between wavelengths is used in the illuminating step to determine an initial hemoglobin oxygenation level and a second wavelength gap, dependent upon the initial hemoglobin oxygenation level, is used thereafter.